ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. (Q45124918)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 February 2013

Language	Label	Description	Also known as
English	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.	scientific article published on 20 February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Olivier Hermine

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hanneke C Kluin-Nelemans

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Pier Luigi Zinzani

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

M Dreyling

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C Thieblemont

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Gallamini

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

S Le Gouill

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

E Iannitto

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

S Pileri

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

J Rodriguez

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

N Schmitz

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Wotherspoon

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

20 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

857-877

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425945%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Splenic marginal zone lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Splenic marginal zone lymphoma: a prognostic model for clinical use.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Splenic marginal-zone lymphoma: a distinct clinical and pathological entity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Rituximab monotherapy is highly effective in splenic marginal zone lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Advances in the understanding of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The complex landscape of genetic alterations in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

CDK4andMDM2Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-typeINK4a/ARFLocus

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Current treatment standards and emerging strategies in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Front-line treatment of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Treatment of elderly patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Treatment of older patients with mantle-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

How I treat mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Therapeutic concepts in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Mantle cell lymphoma: the promise of new treatment options

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Treatment of younger patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

A novel subset of T-helper cells: follicular T-helper cells and their markers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS643

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45124918&oldid=1521051879"